798 related articles for article (PubMed ID: 18370240)
1. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics in rheumatoid arthritis.
Sen D; Paul JR; Ranganathan P
Methods Mol Biol; 2014; 1175():625-60. PubMed ID: 25150878
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.
Aluko A; Ranganathan P
Methods Mol Biol; 2022; 2547():527-567. PubMed ID: 36068476
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate pharmacogenetics in rheumatoid arthritis.
Brinker RR; Ranganathan P
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
[TBL] [Abstract][Full Text] [Related]
5. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
Simon LS
Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
Taniguchi A; Urano W; Tanaka E; Kamatani N
Nihon Rinsho; 2007 Feb; 65(2):371-9. PubMed ID: 17302286
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of therapies in rheumatoid arthritis.
Ranganathan P
Drugs Today (Barc); 2005 Dec; 41(12):799-814. PubMed ID: 16474855
[TBL] [Abstract][Full Text] [Related]
8. Current concepts in the genetic diagnostics of rheumatoid arthritis.
Nagy ZB; Csanád M; Tóth K; Börzsönyi B; Demendi C; Rigó J; Joó JG
Expert Rev Mol Diagn; 2010 Jul; 10(5):603-18. PubMed ID: 20629510
[TBL] [Abstract][Full Text] [Related]
9. An update on methotrexate pharmacogenetics in rheumatoid arthritis.
Ranganathan P
Pharmacogenomics; 2008 Apr; 9(4):439-51. PubMed ID: 18384257
[TBL] [Abstract][Full Text] [Related]
10. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
Schiff MH; Whelton A
Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of disease-modifying anti-rheumatic drugs.
Tanaka E; Taniguchi A; Urano W; Yamanaka H; Kamatani N
Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):233-47. PubMed ID: 15121042
[TBL] [Abstract][Full Text] [Related]
12. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
13. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?
Stamp L; Roberts R; Kennedy M; Barclay M; O'Donnell J; Chapman P
Biomed Pharmacother; 2006 Dec; 60(10):678-87. PubMed ID: 17071051
[TBL] [Abstract][Full Text] [Related]
14. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
15. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
Ranganath VK; Furst DE
Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
[TBL] [Abstract][Full Text] [Related]
16. The role of anti-malarials in rheumatoid arthritis--the American experience.
Khraishi MM; Singh G
Lupus; 1996 Jun; 5 Suppl 1():S41-4. PubMed ID: 8803910
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.
Kapral T; Stamm T; Machold KP; Montag K; Smolen JS; Aletaha D
Arthritis Res Ther; 2006; 8(2):R46. PubMed ID: 16507172
[TBL] [Abstract][Full Text] [Related]
18. Leflunomide for rheumatoid arthritis.
Drug Ther Bull; 2000 Jul; 38(7):52-4. PubMed ID: 11027115
[TBL] [Abstract][Full Text] [Related]
19. [DMARDs (disease-modifying antirheumatic drugs)].
Tanaka E; Yamanaka H
Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
[TBL] [Abstract][Full Text] [Related]
20. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
